What is Accellix?
Accellix operates at the intersection of advanced diagnostics and therapeutic manufacturing, providing a proprietary platform designed to streamline quality control processes. The Accellix system, a benchtop flow cytometer utilizing capillary cartridges and integrated dry reagents, addresses the industry-wide challenge of reproducibility in cell analysis. By facilitating the migration of complex cell assays to an automated, multi-parametric platform, the company empowers biopharmaceutical developers to accelerate their pipelines. This technological infrastructure is essential for firms aiming to meet stringent QC requirements while scaling life-changing therapies for global patient populations. The company's focus on automation and ease of use positions it as a foundational partner for clinical-stage biotech entities.
How much funding has Accellix raised?
Accellix has raised a total of $19.6M across 3 funding rounds:
Debt
$150K
Series D
$9.5M
Private Equity
$10M
Debt (2020): $150K with participation from PPP
Series D (2020): $9.5M led by bioMérieux SA
Private Equity (2021): $10M supported by BroadOak Capital Partners
Key Investors in Accellix
bioMérieux SA
A global leader in in vitro diagnostics, bioMérieux specializes in microbiology and molecular biology solutions for clinical and industrial applications.
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in direct investment and banking services for life sciences and biopharma services companies.
PPP
Public-Private Partnership
What's next for Accellix?
With the recent influx of capital, Accellix is well-positioned to scale its commercial operations and expand the reach of its diagnostic platform. The strategic focus will likely shift toward deepening market penetration within the cell and gene therapy ecosystem, where the demand for standardized, high-throughput QC solutions continues to outpace existing legacy methodologies. As the company matures, it is expected to leverage this financial runway to enhance its R&D capabilities, potentially introducing new cartridge-based assays that further simplify the workflow for complex therapeutic monitoring. This growth trajectory suggests a transition toward becoming an indispensable utility in the biopharma supply chain, ensuring that the next generation of medical breakthroughs can be manufactured with the precision and reliability required for regulatory approval and commercial success.
See full Accellix company page
